Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
Inclusion Criteria:
Exclusion Criteria:
None
Other protocol-defined inclusion/exclusion criteria may apply.
novartis.email@novartis.com+41613241111